HK1032348A1 - Chronic myeloid leukemia (cml) therapy. - Google Patents

Chronic myeloid leukemia (cml) therapy.

Info

Publication number
HK1032348A1
HK1032348A1 HK01102201A HK01102201A HK1032348A1 HK 1032348 A1 HK1032348 A1 HK 1032348A1 HK 01102201 A HK01102201 A HK 01102201A HK 01102201 A HK01102201 A HK 01102201A HK 1032348 A1 HK1032348 A1 HK 1032348A1
Authority
HK
Hong Kong
Prior art keywords
cml
therapy
myeloid leukemia
chronic myeloid
chronic
Prior art date
Application number
HK01102201A
Other languages
English (en)
Inventor
Mary Ellen Rybak
Esther Helen Rose
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1032348A1 publication Critical patent/HK1032348A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK01102201A 1999-04-08 2001-03-26 Chronic myeloid leukemia (cml) therapy. HK1032348A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28836999A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
HK1032348A1 true HK1032348A1 (en) 2001-07-20

Family

ID=23106810

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01102201A HK1032348A1 (en) 1999-04-08 2001-03-26 Chronic myeloid leukemia (cml) therapy.

Country Status (22)

Country Link
EP (2) EP1043024B1 (hu)
JP (2) JP2000309541A (hu)
CN (1) CN1364089A (hu)
AR (1) AR023390A1 (hu)
AT (1) ATE297216T1 (hu)
AU (2) AU777456B2 (hu)
BR (1) BR0009642A (hu)
CA (1) CA2303765A1 (hu)
CO (1) CO5170411A1 (hu)
DE (1) DE60020635T2 (hu)
DK (1) DK1043024T3 (hu)
ES (1) ES2243166T3 (hu)
HK (1) HK1032348A1 (hu)
HU (1) HUP0200731A3 (hu)
MY (1) MY127276A (hu)
NO (1) NO20014850L (hu)
NZ (1) NZ514417A (hu)
PE (1) PE20010226A1 (hu)
PT (1) PT1043024E (hu)
TW (1) TWI271196B (hu)
WO (1) WO2000061173A2 (hu)
ZA (1) ZA200108172B (hu)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020977A2 (en) * 2001-08-31 2003-03-13 The University Court Of The University Of Glasgow Nucleotide repeats assay

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates

Also Published As

Publication number Publication date
NZ514417A (en) 2003-10-31
EP1043024B1 (en) 2005-06-08
MY127276A (en) 2006-11-30
AU777456B2 (en) 2004-10-14
PT1043024E (pt) 2005-10-31
JP2007070367A (ja) 2007-03-22
AU4451500A (en) 2000-11-14
DK1043024T3 (da) 2005-07-04
EP1535624A1 (en) 2005-06-01
AU2004242456A1 (en) 2005-01-20
JP2000309541A (ja) 2000-11-07
DE60020635T2 (de) 2006-05-04
HUP0200731A3 (en) 2002-09-30
PE20010226A1 (es) 2001-02-26
ZA200108172B (en) 2003-01-06
HUP0200731A2 (en) 2002-08-28
DE60020635D1 (de) 2005-07-14
NO20014850D0 (no) 2001-10-05
WO2000061173A3 (en) 2001-01-25
BR0009642A (pt) 2002-01-08
AR023390A1 (es) 2002-09-04
EP1043024A3 (en) 2000-12-20
NO20014850L (no) 2001-12-07
CN1364089A (zh) 2002-08-14
ES2243166T3 (es) 2005-12-01
ATE297216T1 (de) 2005-06-15
AU2004242456B2 (en) 2007-02-15
WO2000061173A2 (en) 2000-10-19
EP1043024A2 (en) 2000-10-11
CA2303765A1 (en) 2000-10-08
CO5170411A1 (es) 2002-06-27
TWI271196B (en) 2007-01-21

Similar Documents

Publication Publication Date Title
HK1048642A1 (en) Fap-activated anti-tumor compounds.
PL355109A1 (en) Tert.
GB0017635D0 (en) Antitumor combined therapy
MXPA03001419A (es) Combinacion terapeutica de un inhibidor de la proteina de transferencia de esteres de colesterol y atorvastatina.
ZA99454B (en) Novel dosage form.
HK1037453A1 (en) Earphone.
HK1041649A1 (en) Cilostazol preparation.
MXPA03009791A (es) Ligandos para el receptor de melanocortina.
ZA200107411B (en) Melanocortin receptor ligands.
ZA200108530B (en) 4,5,6,7-tetrahydroindazole derivatives as antitumor agents.
HK1054383A1 (en) Trans olefinic glucokinase activators.
HK1046139A1 (en) Glucokinase activators.
HK1048969A1 (en) Dual droplet size printead.
ZA200300793B (en) Substituted-triazolopyrimidines as anticancer agents.
MXPA03002691A (es) Ligandos de receptor de melanocortina.
ZA992255B (en) Antitumor synergetic composition.
HK1039278A1 (en) Pegylated interferon alfa-ccr5 antagonist combination hiv therapy.
HK1053470A1 (en) 4-Pyridinyln-acyl-l-phenylalanines.
HK1041482A1 (en) Naphtho-and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents.
HUP0203153A3 (en) Combination chemotherapy
GB0027552D0 (en) Anti-tumor compounds
HK1032348A1 (en) Chronic myeloid leukemia (cml) therapy.
ZA200110046B (en) Therapeutic agents.
HK1042249A1 (zh) 抗腫瘤的協同組合物
ZA200004598B (en) Fortification process.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150406